top of page
accueil def.png

Reach the full potential of genome editing

AlgenScribe is a biotechnology company developing a gene editing platform to improve human health.

Company

Gene editing has the potential to revolutionize the way we cure severe diseases.

​

Algenscribe is a Biotechnology company developing a gene editing platform to improve human health.

Our strategy is to apply our unique toolbox for gene replacement and base editing.

We have a particular focus on gene replacement.

​

Our mission is to translate our technologies into therapeutics.

eprouvette.png
gene thérapies.png

Gene
Therapy

 

cell.png

Cell
engineering
tools

biologics.png

Biologics
 

small molécule.png

Molecular Diagnostics

Genome
Editing

 

Company

Science

Science

The foundation of our technologies is based on more than 10 years of development performed by Algentech in plant cell models.

Algenscribe owns all IP rights for human health applications.​

Our proprietary platform significantly increases homologous recombination efficiency and addresses key limitations associated with nuclease-based gene editing approaches. This breakthrough enables more efficient and precise gene replacement and base editing strategies.

​

​

DNA is cut in a targeted site by molecular scissors (nucleases).

The cell repairs this break with 2 processes:

Non-homologous End Joining (NHEJ) or Homology-Directed Repair (HDR).

​

Gene inactivation

schéma.png

NHEJ

NHEJ is naturally more efficient than HDR

HDR

Module 1: Amplified donor DNA

guided to the insertion site

Mutations

​

Gene repair by HDR

Module 2: Enzyme to foster HDR

Management team

Management team

zampatti.png

Frédéric Zampatti

Co-founder & CEO

​

M. Zampatti has 15 years of experience in supporting and financing innovative companies.

He financed and support for two seed funds various companies in the fields of biotechnology and diagnostics. Frédéric was a project manager at Genopole (Evry) and has an experience of deputy general manager in the start up Nutrivercell (sold to EA pharma group in 2017). He is graduated from Toulouse Business School.

Malcuit.png

Dr Isabelle Malcuit

Scientific co Founder

​

Dr Malcuit holds a PhD in plant virology received in 1998 from the department of genetics, Trinity College (Dublin, Ireland). Dr Malcuit has extensive experience in genetics and biotechnology. Prior to founding Algentech, she held the position of senior research associate at the Sainsbury Laboratory (Norwich, UK), in charge of the programme for functional genomics using VIGS (Virus-Induced Gene Silencing). She is co-inventor on 7 patent families owned by Algentech.

Sorokin.png

Dr Alexander Sorokin

Scientific co Founder

​

Dr Sorokin has more than 20 years’ experience in genetics, agronomy and biotechnology. He obtained his PhD in plant genetics obtained in 1991 from the school of Agronomy in Minsk for his work on wheat and triticale genetics. Prior to founding Algentech he held the position of senior research associate at the Sainsbury Laboratory (Norwich, UK), in charge of technology development and consultant at Plant Bioscience Ltd (Norwich, UK). He is co-inventor on 7 patent families owned by Algentech.

Partnerships

Partnerships

Algenscribe values collaborations with industrial partners, foundations and academic institutions to accelerate the development of its genome editing platform.

Targeted fields of application:

  • Therapeutics: cell and gene therapy

  • Bioproduction


For partnering opportunities, please contact us.

​

​

​

Partners

We are eager to set up collaborations with academic institutions, foundations and industrial partners.

​

Industrial partnership

​

​

​

 

 

Algentech specialises in the development of cutting edge technologies for gene editing and synthetic biology  for multi-sectorial applications.

Algentech Logo.png
They support and /or finance us:
spartners.png
Logo adhérent Medicen.png
la french tech.png
bpi france.png
Logo Mabdesign.png
IPCA_Logo.png
région sud.png
Logo-Eurobiomed-.png
Logo Genopole.png
Logo genother.png
News
fond.png

News

logo algenscribe.png

​61 avenue Simone Veil

06200 Nice

contact@algenscribe.com

Once positions arise, we will post a job listing.​

Les postes à pouvoir feront l'objet d'une annonce.​

Contact us

Thanks for contacting us!

Contact
bottom of page